)
Visual
earnings real time
EQL Pharma
EQL Pharma (EQL) investor relations material
EQL Pharma Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Feb, 2026
Executive summary
Achieved record quarterly sales of SEK 118.9 million, a 29% year-over-year increase, rebounding from prior supply chain challenges.
Gross margin improved to 42%, and EBITA/EBITDA margin reached 21%, both showing recovery from previous disruptions.
Supply chain improvements and better product availability, especially for Memprex, drove performance.
Strategic focus shifting from rapid growth to profitability and operational efficiency.
Two new management team members recruited to enhance international commercial and financial capabilities.
Financial highlights
Net sales for Q3: SEK 118.9 million, up from SEK 92.2 million year-over-year; April–December: SEK 312.5 million, up from SEK 260.3 million.
Gross margin increased to 42%; EBITA/EBITDA margin at 21%, below the 25% target but a significant rebound.
Pipeline investments totaled nearly SEK 12 million in Q3, similar to last year.
CapEx for the year expected to be SEK 65–70 million, lower than initial guidance due to project delays.
Cash and cash equivalents at period end: SEK 72.7 million, up from SEK 15.6 million year-over-year.
Outlook and guidance
Full-year growth outlook maintained at 15% with an EBITA/EBITDA margin target of 20%.
Q4 expected to be strong in absolute terms, but year-over-year comparison is challenging due to a strong Q4 last year.
Some scrapping of Covid-19 tests expected to negatively impact Q4 margins by 2–4 percentage points.
Multiple major product launches planned for next year, including Memprex in France and Germany.
No significant OpEx increase anticipated next year; cost-saving initiatives underway.
Why is 2025/26 sales growth forecast 15%?
Germany/Netherlands market entry strategy
How do new hires support international growth?
Savings package impact on EBITDA margin
Memprex/Meloson growth drivers beyond UK/Nordics
Leverage management vs. new investment funding
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- FSV
Annual revenue up 5% to $5.50B; Adjusted EBITDA and EPS both saw double-digit growth. - QLINEA
Over 400% revenue growth in 2025, with US expansion and breakeven targeted for 2027. - OMV
Clean CCS Operating Result down 10% year-over-year, with strong cash flow and 9.3% dividend yield. - UPM
Strong Q4 cash flow and strategic moves support growth despite lower sales and EBIT. - GSK
7% sales growth and 12% EPS rise, led by Specialty and HIV, with strong 2026 outlook. - UBSG
Net profit surged 56% YoY, with accelerated capital repatriation and robust capital ratios. - EQNR
Record production, strong cash flow, and 3% growth outlook drive robust capital returns. - EVR
Record $3.9bn net revenue, 45% from non-M&A, margin expansion, and strong capital return. - GODREJAGRO
Q3 FY26 revenue up 11% to ₹2,718 crore, with strong profit and margin growth across key segments. - HUDCO
Net profit up to ₹2,053.06 crore, record disbursements, strong asset quality, and robust liquidity.
Next EQL Pharma earnings date
Q4 25/268 May, 2026
EQL Pharma
Next EQL Pharma earnings date
Q4 25/268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
EQL Pharma AB engages in the development, marketing, and sale of specialty and generic medicines to pharmacies and hospitals in Europe. It specializes in the treatment of male infertility by proactive production and sale of medicines under its owned trademarks to end consumers, private actors as well as public hospitals and pharmacies. The company was founded in 2006 and is based in Lund, Sweden.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage